We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
+4.47%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$563M
AUM Growth
+$59.4M
Cap. Flow
+$52M
Cap. Flow %
9.23%
Top 10 Hldgs %
30.6%
Holding
102
New
10
Increased
33
Reduced
31
Closed
5

Top Buys

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$14.5M
2
REGN icon
Regeneron Pharmaceuticals
REGN
+$14.4M
3
BIIB icon
Biogen
BIIB
+$11.1M
4
CELG
Celgene Corp
CELG
+$8.17M
5
ENDP
Endo International plc
ENDP
+$7.77M

Top Sells

Rank Stock Value
1
ALKS icon
Alkermes
ALKS
+$11.1M
2
STJ
St Jude Medical
STJ
+$9.9M
3
MDVN
MEDIVATION, INC.
MDVN
+$6.07M
4
PRGO icon
Perrigo
PRGO
+$4.25M
5
LH icon
Labcorp
LH
+$3.76M

Sector Composition

Rank Sector Weight
1 Healthcare 93.53%
2 Financials 1.45%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALXN
1
DELISTED
Alexion Pharmaceuticals
ALXN
$26M 4.63%
223,082
+102,082
+84% +$14.5M
GILD icon
2
Gilead Sciences
GILD
$162B
$20M 3.56%
240,000
+60,000
+33% +$5.32M
CELG
3
DELISTED
Celgene Corp
CELG
$19.6M 3.49%
199,000
+79,000
+66% +$8.17M
BIIB icon
4
Biogen
BIIB
$30B
$19.3M 3.44%
80,000
+42,000
+111% +$11.1M
LLY icon
5
Eli Lilly
LLY
$1.02T
$18.5M 3.29%
235,000
+40,000
+21% +$3.01M
REGN icon
6
Regeneron Pharmaceuticals
REGN
$78.5B
$17.3M 3.07%
49,500
+37,500
+313% +$14.4M
INCY icon
7
Incyte
INCY
$24.2B
$13.6M 2.41%
170,000
– –
PFE icon
8
Pfizer
PFE
$143B
$13.2M 2.34%
395,250
-105,400
-21% -$3.36M
CI icon
9
Cigna
CI
$73.7B
$12.7M 2.25%
99,000
+30,000
+43% +$3.96M
AGN
10
DELISTED
Allergan plc
AGN
$12M 2.13%
52,000
+10,000
+24% +$2.31M
UNH icon
11
UnitedHealth
UNH
$376B
$12M 2.13%
85,000
+25,000
+42% +$3.33M
BMRN icon
12
BioMarin Pharmaceuticals
BMRN
$11.6B
$11.7M 2.07%
150,000
-40,000
-21% -$3.4M
CVS icon
13
CVS Health
CVS
$133B
$11.5M 2.04%
120,000
+15,000
+14% +$1.49M
ABMD
14
DELISTED
Abiomed Inc
ABMD
$11.5M 2.04%
105,000
-20,000
-16% -$1.99M
MDT icon
15
Medtronic
MDT
$109B
$11M 1.96%
127,000
-10,000
-7% -$809K
ALNY icon
16
Alnylam Pharmaceuticals
ALNY
$27.5B
$10.8M 1.92%
195,000
+70,000
+56% +$4.41M
BMY icon
17
Bristol-Myers Squibb
BMY
$133B
$10.1M 1.79%
137,000
-5,000
-4% -$353K
ENDP
18
DELISTED
Endo International plc
ENDP
$9.9M 1.76%
635,200
+375,200
+144% +$7.77M
JAZZ icon
19
Jazz Pharmaceuticals
JAZZ
$15.9B
$9.89M 1.76%
70,000
+40,000
+133% +$5.9M
AMGN icon
20
Amgen
AMGN
$208B
$9.36M 1.66%
61,500
+16,500
+37% +$2.57M
ESRX
21
DELISTED
Express Scripts Holding Company
ESRX
$8.79M 1.56%
116,000
+10,000
+9% +$735K
ZBH icon
22
Zimmer Biomet
ZBH
$18.2B
$8.55M 1.52%
73,130
-20,600
-22% -$2.33M
AET
23
DELISTED
Aetna Inc
AET
$8.18M 1.45%
67,000
– –
CPHD
24
DELISTED
Cepheid Inc
CPHD
$8M 1.42%
260,000
+110,000
+73% +$3.33M
CNC icon
25
Centene
CNC
$30.7B
$7.97M 1.42%
223,424
-60,000
-21% -$1.88M
1
2 3 4 5

Similar funds

BBI
Baxter Bros Inc Riverside, Connecticut $810M AUM 16.24% 1-Year Est. Return
SSG
Summit Securities Group New York $810M AUM 27.35% 1-Year Est. Return
PS
Portfolio Strategies Monsey, New York $811M AUM 28.91% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
DWA
Dorsey Wright & Associates Pasadena, California $807M AUM 65.46% 1-Year Est. Return
SLG
Stanley-Laman Group Berwyn, Pennsylvania $814M AUM 40.24% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return

Rhenman & Partners Asset Management's Q2 2016 Portfolio in Review

As of Q2 2016, Rhenman & Partners Asset Management held 102 positions worth $563M, up 12% from $504M the previous quarter. Its ten largest holdings account for 31% of the portfolio.

Rhenman & Partners Asset Management deployed $52M of net new capital in Q2 2016, opening 10 new positions and adding to 33 existing holdings. Its largest new stake was Pediatrix Medical: 80,000 shares worth $5.79M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 93% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Alkermes, an estimated $11.1M trimmed.

  • Rhenman & Partners Asset Management's largest Q2 2016 buy was Pediatrix Medical: 80,000 shares worth $5.79M.
  • Rhenman & Partners Asset Management added most to Alexion Pharmaceuticals in Q2 2016, an estimated $14.5M increase.
  • Rhenman & Partners Asset Management's biggest Q2 2016 reduction was Alkermes, cutting an estimated $11.1M.
  • Rhenman & Partners Asset Management fully exited St Jude Medical in Q2 2016, selling an estimated $9.9M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 31% of its $563M portfolio in Q2 2016.
  • Rhenman & Partners Asset Management opened 10 new positions and closed 5 in Q2 2016.
  • Rhenman & Partners Asset Management's portfolio value rose 12% quarter-over-quarter to $563M.

Based on Rhenman & Partners Asset Management's 13F filing for Q2 2016, filed 1 Aug 2016.